Evidence for Highly Variable, Region-Specific Patterns of T-Cell Epitope Mutations Accumulating in<i> Mycobacterium tuberculosis Strains</i> by Ramaiah, Arunachalam et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.3389/fimmu.2019.00195
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Ramaiah, A., Nayak, S., Rakshit, S., Manson, A. L., Abeel, T., Shanmugam, S., ... Vyakarnam, A. (2019).
Evidence for Highly Variable, Region-Specific Patterns of T-Cell Epitope Mutations Accumulating in
Mycobacterium tuberculosis Strains. Frontiers in Immunology, 10, [195].
https://doi.org/10.3389/fimmu.2019.00195
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
ORIGINAL RESEARCH
published: 13 February 2019
doi: 10.3389/fimmu.2019.00195
Frontiers in Immunology | www.frontiersin.org 1 February 2019 | Volume 10 | Article 195
Edited by:
Amy Rasley,
Lawrence Livermore National
Laboratory, United States
Reviewed by:
Werner Solbach,
Universität zu Lübeck, Germany
Daniel M. Altmann,
Imperial College London,
United Kingdom
*Correspondence:
Annapurna Vyakarnam
annapurnavyakarnam@gmail.com;
anna.vyakarnam@kcl.ac.uk
†Present Address:
Arunachalam Ramaiah,
Division of Pulmonary and Critical
Care Medicine, Stanford University
School of Medicine, Stanford, CA,
United States
‡These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Microbial Immunology,
a section of the journal
Frontiers in Immunology
Received: 13 July 2018
Accepted: 23 January 2019
Published: 13 February 2019
Citation:
Ramaiah A, Nayak S, Rakshit S,
Manson AL, Abeel T, Shanmugam S,
Sahoo PN, John AJUK,
Sundaramurthi JC, Narayanan S,
D’Souza G, von Hoegen P,
Ottenhoff THM, Swaminathan S,
Earl AM and Vyakarnam A (2019)
Evidence for Highly Variable,
Region-Specific Patterns of T-Cell
Epitope Mutations Accumulating in
Mycobacterium tuberculosis Strains.
Front. Immunol. 10:195.
doi: 10.3389/fimmu.2019.00195
Evidence for Highly Variable,
Region-Specific Patterns of T-Cell
Epitope Mutations Accumulating in
Mycobacterium tuberculosis Strains
Arunachalam Ramaiah 1†, Soumya Nayak 1‡, Srabanti Rakshit 1‡, Abigail L. Manson 2,
Thomas Abeel 2, Sivakumar Shanmugam 3, Pravat Nalini Sahoo 1,
Anto Jesuraj Uday Kumar John 4, Jagadish Chandrabose Sundaramurthi 3,
Sujatha Narayanan 3, George D’Souza 4, Paul von Hoegen 5, Tom H. M. Ottenhoff 6,
Soumya Swaminathan 3, Ashlee M. Earl 2 and Annapurna Vyakarnam 1,7*
1Centre for Infectious Disease Research, Indian Institute of Science, Bangalore, India, 2 Broad Institute of MIT and Harvard,
Cambridge, MA, United States, 3National Institute for Research in Tuberculosis (ICMR), Chennai, India, 4Department of
Pulmonary Medicine, St. John’s Research Institute, Bangalore, India, 5 JPT Peptide Technologies GmbH, Berlin, Germany,
6Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands, 7Department of Infectious
Diseases, Faculty of Life Sciences & Medicine, School of Immunology and Microbial Sciences, King’s College London,
London, United Kingdom
Vaccines that confer protection through induction of adaptive T-cell immunity rely on
understanding T-cell epitope (TCE) evolution induced by immune escape. This is poorly
understood in tuberculosis (TB), an ancient, chronic disease, where CD4 T-cell immunity
is of recognized importance. We probed 905 functionally validated, curated human
CD4T cell epitopes in 79 Mycobacterium tuberculosis (Mtb) whole genomes from India.
This screen resulted in identifying 64 mutated epitopes in these strains initially using
a computational pipeline and subsequently verified by single nucleotide polymorphism
(SNP) analysis. SNP based phylogeny revealed the 79 Mtb strains to cluster to East
African Indian (EAI), Central Asian Strain (CAS), and Beijing (BEI) lineages. Eighty-nine
percent of the mutated T-cell epitopes (mTCEs) identified in the 79 Mtb strains from
India has not previously been reported. These mTCEs were encoded by genes with high
nucleotide diversity scores including seven mTCEs encoded by six antigens in the top
10% of rapidly divergent Mtb genes encoded by these strains. Using a T cell functional
assay readout, we demonstrate 62% of mTCEs tested to significantly alter CD4 T-cell
IFNγ and/or IL2 secretion with associated changes in predicted HLA-DR binding affinity:
the gain of function mutations displayed higher predicted HLA-DR binding affinity and
conversely mutations resulting in loss of function displayed lower predicted HLA-DR
binding affinity. Most mutated antigens belonged to the cell wall/cell processes, and,
intermediary metabolism and respiration families though all known Mtb proteins encoded
mutations. Analysis of the mTCEs in an SNP database of 5,310 global Mtb strains
identified 82% mTCEs to be significantly more prevalent in Mtb strains isolated from
India, including 36 mTCEs identified exclusively in strains from India. These epitopes had
a significantly higher predicted binding affinity to HLA-DR alleles that were highly prevalent
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in India compared to HLA-DR alleles rare in India, highlighting HLA-DR maybe an
important driver of these mutations. This first evidence of region-specific TCE mutations
potentially employed by Mtb to escape host immunity has important implications for TB
vaccine design.
Keywords: Mycobacterium tuberculosis, genome sequence, T-cell epitopes, evolution, immune response, TB
vaccine
INTRODUCTION
A well-recognized consequence of adaptive immune responses
is the occurrence of pathogen immune escape variants arising
through positive selection, an effective strategy for pathogens to
persist by evading host immunity and creating pathogen diversity
(1). In the case of Mycobacterium tuberculosis (Mtb), a highly
successful bacterial pathogen that has effectively co-evolved with
the human host for thousands of years, there is clear evidence
for emergence of drug selection variants (2, 3). However, there is
little evidence that the host immune response can exert sufficient
selection pressure to induce pathogen escape.
Adaptive immune responses, particularly T-cell responses,
have been implicated in protective immunity to tuberculosis
(TB), with rapid disease progression noted in humans and animal
models with T cell-deficiencies (4–6). Among T lymphocytes,
there is well-documented evidence that CD4T cells are essential
for protection (7). Thus, HIV-induced CD4T cell loss is a major
predisposing factor for acquisition of active TB, while restoration
of CD4 T-cells following antiretroviral therapy reduces this
enhanced susceptibility to TB (3). Furthermore, Mtb-specific
interferon gamma (IFNγ) and interleukin-2 (IL-2) secreting
CD4, rather than CD8T cells, correlate with protection (8–
11). Despite a critical role for specific CD4 T-cells in protective
immunity, bacterial persistence in an infected host is common
and can lead to subsequent reactivation and transmission of
TB. The mechanisms underlying this persistence may include
bacterial disruption of antigen presentation and interference with
T-cell effector mechanisms (12). In addition, antigenic variation
arising from host immune pressure can lead to immune escape;
to what extent this contributes to Mtb persistence in an infected
host is poorly understood.
Very few studies have probed the evolution of T-cell epitopes
(TCEs) encoded in Mtb genomes. The study of Comas et al.
(13), initially showed Mtb-specific TCEs to be highly conserved
in a small study of 21 strains, despite known continuous
diversification of Mtb genomes. This analysis was based on
probing the sequence of Mtb strains for conservation vs.
(coding) mutations in TCEs curated in the Immune Epitope
Database and Analysis Resources (IEDB) (14). More recently
the same group confirmed this observation using an expanded
collection of 216 Mtb strains (15). Additionally, using a
functional genomics approach, they found several new TCEs in
proteins that selectively mapped to more rapidly diversifying
regions of the Mtb genome that also impacted T-cell interferon
gamma release (15), thus providing important functional genetic
evidence supporting T-cell immune escape in Mtb infection. The
significance of this observation relies on understanding whether
TCE evolution is a general phenomenon more commonly found
in TB, and, importantly establishing whether similar mutation
patterns are reproduced in Mtb strains circulating in other
geographic regions of the world. To address this important
issue, we first analyzed functionally verified TCEs curated in
IEDB in 79 Mtb whole genomes isolated from subjects in
India. The mutations identified in these epitopes were then
contextualized to corresponding non-synonymous changes using
a single nucleotide polymorphism (SNP) database of 5,310 Mtb
strains circulating worldwide, that also included the 79 whole
genomes from India, as reported in our recent studies of drug
resistance mutations in these strains (16, 17). Our current study
therefore aims to provide a highly comprehensive analysis to date
of TCE mutations in Mtb strains.
We hypothesized that, based on inherent lineage differences
combined with population related HLA differences, which can
significantly imprint T-cell epitope evolution (18), the pattern,
specificity and nature of T-cell epitope mutations in Mtb strains
prevalent in India will differ fromMtb strains circulating globally
outside India. Evidence is provided in support of this hypothesis.
MATERIALS AND METHODS
Study Population for Isolation of Mtb
Strains From India
Extended clinical details including ethics of infected subjects and
strain collection is detailed in our previous publications, where
220 strains were studied from India (16, 17). Briefly, patients
attending any of the designated microscopy centers in 5 blocks
of Tiruvallur district, Tamil Nadu, India between May 1999 and
December 2003, with a history of cough of 3 weeks or more were
investigated for tuberculosis. Initially, two sputum specimens
(one spot and one overnight specimen) were tested by sputum
smear microscopy using the Ziehl–Neelsen method (19). Those
patients diagnosed to have TB (on sputum smear microscopy or
clinical grounds) were categorized (based on previous history of
treatment) and initiated on the appropriate treatment regimen
by the medical officers at the respective centers [Category I, II,
III of the Revised National Tuberculosis Program (RNTCP)].
Their response to treatment was monitored by monthly clinical
response as well as sputum smear examination at 2 months
and at end of treatment. Two additional sputum samples were
collected from these patients for investigations at National
Institute for Research in Tuberculosis (NIRT), Chennai, India.
Further, patients with suspected drug resistance from all over
Tamil Nadu of India were referred to NIRT for drug susceptibility
testing. Three sputum specimens were collected at baseline and
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patients initiated on treatment, based on history and available
drug susceptibility testing (DST) (Category IV and V of RNTCP).
They were followed every month with a clinical review and
sputum examination.
Bacteriologic Methods and DNA Isolation
The method for bacterial culture and DNA extraction were
detailed (16, 17). In brief, sputum samples were transported
to NIRT on the same day and were processed for culture
on Löwenstein-Jensen medium. Culture positive isolates were
selected and subjected to identification, and susceptibility
testing. Seventy-nine Mtb isolates were considered for further
studies. Resistance to Rifampicin, Isoniazid and Ethambutol was
determined by the minimal inhibitory concentration method
(MIC), and resistance to streptomycin was determined by
the Resistance Ratio (RR) method (20, 21). Genomic DNA
was extracted from Mtb cultures by standard CTAB–NaCl
extraction method (22). Spoligotyping was performed using
standard protocol (23). We analyzed our spoligotyping data on a
global scale through comparison with the international SpolDB4
database. All 79 Mtb strains were broadly classified into three
groups as follows: drug sensitive (DS): susceptible to all the
drugs tested, including streptomycin, isoniazid, rifampicin and
ethambutol; Poly-resistant (PR): resistant to more than one first-
line anti-TB drug, other than isoniazid + rifampicin; Multi drug
resistant (MDR): resistant to rifampicin and isoniazid in addition
to any other drug tested (http://www.who.int/tb/areas-of-work/
drug-resistant-tb/types/en/).
Genome Sequencing, Assembly, and
Annotation of 79 Mtb Strains
Library preparation and whole genome sequencing (WGS) were
performed as previously described (16, 17, 24, 25). All genomes
were uniformly annotated by transferring annotations from
the reference, M. tuberculosis H37Rv. The reference (accession
#CP003248.2) was aligned to draft assemblies using NUCmer
(26). This alignment was used to map reference genes over to
the target genomes. For those genes not clearly mapping to
M. tuberculosis H37Rv, the protein-coding genes were predicted
with the software tool Prodigal (27). tRNAs were identified
by tRNAscan-SE (28) and rRNA genes were predicted using
RNAmmer (29). Gene product names were assigned based on
top Blast hits against the SwissProt protein database (≥70%
identity and ≥70% query coverage), and protein family profile
search against the TIGRFAM Hmmer Equivalogs. Additional
annotation analyses performed include Pfam (30), TIGRFAM
(31), Kyoto Encyclopedia of Genes and Genomes (KEGG) (32),
clusters of orthologous groups (COG) (33), Gene Ontology (GO)
(34), EFICAz (35), SignalP (36), and TransmembraneHelices and
Hidden Markov Model (TMHMM) (37).
Verification to Remove Paralogs
As it is important to ensure that epitopes identified in our
study were identified in true orthologs, rather than in closely
related paralogous proteins, we used established pipelines to
perform orthogroup clustering, including annotation transfer
(24) and SynerClust (available at: https://github.com/SynerClust/
SynerClust), which is based on the Synergy algorithm (38, 39).
This algorithm takes into account both gene similarity and
genomic synteny, leading to more accurate placement of paralogs
into the correct orthogroups.
Our initial selection of orthologs based on reciprocal blast
hits was verified using the Broad’s TB annotation pipeline (39)
for transferring annotations from Mtb H37Rv. According to
this annotation pipeline, genome alignments were performed
to map the genes from the H37Rv reference genome onto each
newly assembled genome (16, 17). If annotated gene names
were available for a particular orthogroup, we verified that the
set of genes sharing the same gene name were found in the
same orthogroup. For genes without annotated gene names
from the annotation pipeline, we used orthogroups calculated
using SynerClust.
Phylogenetic Analysis
Next-generation sequence (NGS) reads from 79 clinical isolates
from India were mapped onto a reference strain, H37Rv
(GenBank #CP003248.2), using BWA version 0.5.9 (40). In
cases in which read coverage of the reference was >200 ×,
reads were down-sampled using Picard (http://broadinstitute.
github.io/picard/) prior to mapping. Positions that varied
relative to the reference were identified using Pilon version 1.5
as described in Walker et al. (41). All sites with unambiguous
SNPs in at least one strain were combined into a concatenated
alignment. Ambiguous positions were treated as missing data.
The concatenated alignment was then used to generate a
midpoint rooted maximum likelihood (ML) phylogenetic tree
in RAxML (version 7.3.3) (42) under a GTRCAT substitution
model with 1,000 bootstrap replicates. Epitope information
was overlaid on the phylogeny using the Peacock software (43).
Each SNP was mapped to a gene locus, and its coding effect was
annotated with VCF annotator (44).
Annotation Based Pipeline for Screening
Mutations in T-Cell Antigens and Their
Epitopes
IEDB was used as a source to retrieve a total of 1,860
experimentally verified T-cell epitopes (TCEs) of Mtb strains
(date 30-Sep-2014). A total of 1,640 out of 1,860 TCEs tested in
humans were unique by epitope identification (ID) number, and
as a result, the remaining 220 identical cum repeated TCEs were
excluded for further analysis. BLASTP searching was done for all
1,640 TCEs against the Mtb reference strain H37Rv to determine
identical epitopes and their locus. We identified 1,783 hits with
100% identity. Elimination of epitopes that matched partially
resulted in 1,723 hits. Of these, 1,465 were unique by ID number;
the remaining 258 hits were duplicates and mapped to more than
one antigen (i.e., antigens from repetitive regions include PE/PPE
family, transposase, phage protein and integrase) and therefore
excluded as independent hits. The identification of the antigens
that these 1,465 epitopes covered was verified using the reference
strain H37Rv as well as the respective bibliographic reference
from IEDB. This resulted in identifying 1,465 TCEs encoded
by 363 T cell proteins/antigens of H37Rv. Overlapping epitopes
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covering a single antigen were next eliminated. This resulted in
identifying a total of 1,101 independent TCEs encoded by 363
Mtb antigens from both non-repetitive and repetitive regions
with 100% identity to H37Rv (Figure S1) that was used to scan
79 Mtb strains.
In order to extract the orthologous 363 T cell antigens
of H37Rv from Mtb strains that we sequenced, stand-alone
reciprocal BLAST and in-house Perl and Shell scripts were
used. We then used an identical method to scan 1,101 TCEs in
these 363 antigens to determine the diversity and evolutionary
patterns of TCEs. If a particular epitope mapped with a
paralogous antigen, then manual mapping was employed.
After excluding the epitopes from repetitive regions, we finally
considered only 905 independent TCEs encoded by 298 antigens.
We analyzed all 905 human CD4+ and CD8+ TCEs as one
group. However, the majority (82%) were CD4T cell epitopes
(Supplementary File 1A); similarly, 91% of the 64 mutated TCEs
(see Results section) were CD4 TCEs (Supplementary File 1B).
Notably, all 298 T cell parent/reference antigens, and 40 of 298
mutated antigens (mAg) carrying mutated TCEs (mTCEs),
were classified into eight different functional categories using
TubercuList (45) (Figure S2).
Matching mTCE to Global SNP Database
and Determining the Global Distribution of
mTCE
All mTCE coordinates were converted to the corresponding
genomic coordinates, with single amino acid changes
corresponding to any one of three positions within the
corresponding codon. If an epitope had more than one mutated
position, then each position was considered individually; that is,
mTCE with two or more mutations were identified by more than
one single nucleotide polymorphism (SNP). Mutant is defined
as amino acid changes within the 79 Indian isolates identified
relative to reference Mtb strain H37Rv or the non-synonymous
mutations in the gene where the epitopes are located. A total
of 64 out of 69 mTCEs identified matched exactly to 66 SNPs
(Supplementary File 2, Sheets 2). We then matched each of the
66 SNPs with the SNPs reported from 5,310 global Mtb strains
in our recent study (16, 17) where the methodology for SNP
identification is described in detail. In Supplementary File 2,
the method used to calculate the global distribution of a given
mTCE is provided. In brief, prevalence or relative enrichment
was calculated as the percentage of strains from India carrying an
mTCE matched SNP (mTCE/SNP) divided by the percentage of
strains outside India carrying the same mTCE/SNP. A prevalence
>2-fold represented mTCE/SNP more prevalent in India; a
prevalence of one, or close to one, represented mTCE/SNP
equally distributed between India and outside India, and a
prevalence <0.5 represented mTCE/SNP more prevalent outside
India. A proportionality test (Fisher’s exact test) adjusted for
multiple comparisons identified mTCE that were significantly
more prevalent in India vs. outside India using Graph Pad
PRISM v7 software. Adjusted p-values were calculated using
p.adjust function of the “R” package with the “BH” correction
method (46). If the value of a p-value is reported as <0.0001 its
value is taken as 0.0001.
MHC Class II Binding Predictions
Major Histocompatibility Complex (MHC) (or) Human
Leukocyte Antigen (HLA) class II binding predictions were
carried out for all mutated 15-mer TCE from 79 Mtb strains
and their corresponding parent epitopes from strain H37Rv for
known Indian alleles (http://www.allelefrequencies.net/) using
widely used IEDB analysis resource consensus tool (47–50)
under IEDB recommended prediction methods. The IEDB
recommended method works based on availability of predictors
and previously observed predictive performance; the IEDB
selection tries to use the best possible method for a given
MHC molecule. This method uses the Consensus approach,
combining NN-align, SMM-align, CombLib, and Sturniolo
to determine if any corresponding predictor is available for
the molecule; otherwise NetMHCIIpan is used. All 20 15-mer
CD4 mTCEs identified and their corresponding parents were
tested for predicted binding to 55 well-recognized Indian HLA
alleles reported in IMGT/HLA database (51). The HLA-DR
alleles employed in this study covered most of the Indian
population (52, 53). The binding prediction results are given in
units of IC 50 nM, such that a lower number indicates higher
affinity. Thus, we considered only those epitopes that were
restricted by the given alleles with predicted binding affinity
score IC ≤ 10 nM, as these high affinity epitopes are more
likely to bind and mount an effective immune response. For
the IEDB recommended method, the median percentile rank
of the aforementioned methods was used as the representative
percentile rank.
Determining the Binding Affinity of mTCE
to HLA-DR Alleles Prevalent in Different
Geographical Regions of the World
The HLA binding affinity was predicted for all 15 mer parent
TCE (N = 20) and their mutants (mTCEs) (N = 20) to a total
of 50 MHC Class II high prevalent alleles (allele frequency ≥
0.01) (http://allelefrequencies.net/) that are classified as follows:
16 alleles highly prevalent in India but also prevalent outside
India (Group A); 11 alleles less prevalent in India but high
prevalent in outside India; and 23 alleles that are not reported
or not common in India, but highly prevalent in rest of the world
(divided as geographical regions: Australia, Europe, North Africa,
North America, North-East Asia, Oceania, South and Central
America, South-East Asia, Sub-Saharan Africa andWestern Asia;
Group B). The latter 23 alleles were reported with high frequency
in at least two of ten geographical regions outside India. A
total of 20 out of 64 15-mer mTCEs were classified into four
groups based on their global geographic distribution in 5,310
Mtb strains as follows: mTCE exclusive to India (n = 10); mTCE
enriched in India (n = 5); mTCE in equal proportion inside and
outside India (n = 2) and mTCE enriched outside India (n = 3)
(Supplementary File 4).
Clinical Samples to Verify Biological
Activity of mTCEs
A total of 130 individuals were prospectively recruited between
April 2015 and April 2016 at St. John’s Medical College and
Hospital and 30ml of peripheral blood was collected from
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them by venipuncture in anticoagulant (ACD/Heparin/EDTA)
depending on the immune assays as part of a Center of Excellence
Grant on HIV-TB Coinfection awarded to AV. Out of 130
subjects recruited, 42 were pulmonary TB patients and the rest
88 healthy individuals were screened by the IGRA test. Of these,
26 were IGRA+ and the remaining IGRA− served as uninfected
healthy controls. For this study, blood and peripheral blood
mononuclear cell (PBMC) from 13 IGRA−, 12 IGRA+, and 11
PTB subjects was available for T cell functional assays. Clinical
information of study participants is summarized in a Table S2
and a detailed clinical file of samples used for this study is
provided in Supplementary File 5. Three clinical groups were
tested for responses to TCE identified in this study: (i) IGRA−,
(ii) IGRA+ or latent TB infection (LTBI), and (iii) pulmonary
TB (PTB).
IGRA− and IGRA+ Subjects
Health Care workers of St. John’s National Academy of Health
Sciences were recruited through internal calls highlighting the
nature and importance of the study. Study subjects were classified
as IGRA+ based on a standard QuantiFERON TB Gold In-
tube test (Qiagen, Germany) results (54). IGRA+ subjects were
classified as LTBI if they had not received preventive/curative
therapy for TB in the past. A total of 88 subjects were recruited
and screened by the IGRA test. Of these, 26 were IGRA+ and
the remaining IGRA− served as uninfected healthy controls, of
which 12 IGRA+ and 13 IGRA− were used in our study for
different assays. Thirteen IGRA− subjects included for the study
of which 46% were males with a median age of 27 years (range
20–39 years). Twelve IGRA+ subjects were included for the study
of which 75% were males with a median age of 32 years (range
25–73 years).
Pulmonary TB
Subjects for this prospective study were enrolled from the Revised
National Tuberculosis Program (RNTCP) clinic of St. John’s
Medical College and Hospital. A diagnosis of pulmonary TB was
ascertained by sputum smear microscopy and culture. Standard
smear grading of 1+, 2+, and 3+ was used to ascertain the
bacterial burden. Smear negative cases of pulmonary TB cases
were diagnosed and classified by the treating clinician from plain
chest radiographs as per the RNTCP standards. All subjects were
treatment naive at the time of enrollment. Consenting adult
patients meeting the above inclusion and exclusion criteria were
included. Sputum samples were collected for reconfirmation of
TB diagnosis by GeneXpert MTB/RIF assay (Cephid, USA). A
total of 11 cases of pulmonary TB were included in the study
of which 90.9% were males with a median age of 37 years
(range 22–66 years).
IFNγ Whole Blood Assay
Peptides were synthesized by JPT Peptide Technologies Ltd
(Berlin, Germany) and reconstituted in dimethyl sulfoxide
(DMSO). Stocks were diluted to 6.25 mg/ml and stored at
−20◦C in aliquots. Within 3–4 h of blood draw, heparinized
whole blood obtained from healthy IGRA+ individuals and
active TB patients was diluted to a final concentration of
1:5 with RPMI 1,640 medium and 100 µl of blood/well was
transferred to 96 well-round-bottom microtiter plates that were
previously loaded with 100 µl each of the candidate peptides at
a final concentration of 10µg/ml. TB-specific antigens, purified
protein derivative (PPD; Staten Serum Institute, Denmark),
and ESAT6/CFP10 fusion protein (55) were added at a
final concentration of 10µg/ml. Phytohemagglutinin (PHA;
5µg/ml) and culture medium (RPMI 1,640) were used as
positive control and negative control, respectively. Plates were
incubated in a 5% CO2 incubator at 37
◦C for 7 days, and
culture supernatants were harvested and stored at −80◦C for
further analysis (56). IFNγ levels were measured in culture
supernatants using the OptEIATMHuman IFNγ ELISA set (BD
Biosciences, UK). Assay background and determining non-
specific effects of peptides: Data in Figure S4B shows background
unstimulated values to be <2pg/ml (median 0, range: 0–2.3
pg/ml) and were subtracted from all stimulated values. IGRA−
subjects were included to highlight the non-specific response
to PPD but specific response to ESAT6/CFP10. Peptides for
this assay were selected based on either the parent or mutant
peptide, when individually tested, inducing a detectable response
over background in all IGRA+ subjects tested. Cells were
stimulated with this peptide pool at 1µg/ml final concentration
for 7 days and background unstimulated control values
were subtracted.
Epitope Specific Responses by
Intracellular Cytokine Staining (ICS) Assay
ICS assay with antigen-stimulated PBMCs was performed as
previously described (57). Cryopreserved PBMCs were taken
out in ice and rapidly thawed in 37◦C water bath, transferred
to 15ml tube containing ∼ 3ml PBS and centrifuged at 2,000
rpm for 5min at RT. 1 × 106 cells were resuspended in
200 µL medium [RPMI-1640 (GIBCO, Invitrogen) with 10%
FCS (GIBCO), 100 U/ml penicillin, 100µg/ml streptomycin,
(SIGMA)], seeded in 96-well round-bottom plates (Costar)
and rested for 2 h. Next PBMCs were either left unstimulated
(negative control) or stimulated with parent and mutant peptides
(10µg/ml), or positive control PHA (1µg/ml), in the presence
of co-stimulatory antibodies (anti-CD28/CD49d, at 0.5µg/mL;
BD Biosciences) at 37◦C and 5% CO2. After 4 h of incubation,
brefeldin A (10µg/ml) was added. Next day, PBMC were
washed after incubation with EDTA and stained with 5 µl
Live/Dead Aqua (Invitrogen) and incubated for 10min at 4◦C
in the dark. Cells were washed and fixed for 20min with 100
µl 1X FACS lysis buffer and permeabilized with 200 µl 1X
BD Perm/Wash buffer for 20min. PBMCs were washed and
stained with 50 µl of intracellular staining cocktail containing
antibodies (BD Biosciences) (CD3 BV570, CD4 BUV397, CD8
BV711, IFNγ-V450, IL2-APC, TNFα-FITC, IL17A-BV605, and
MIP1β-PE) for 30min at RT in the dark. Cells were washed
with 150 µl Perm/Wash buffer and resuspended in ∼100 µl
1% paraformaldehyde (Electron Microscopy Sciences). Stained
samples were acquired with a standard stopping gate set at
100,000 CD3 lymphocytes on a BD FACSAriaTM Fusion flow
cytometer using the BD FACSDivaTM version 8.0.1 software.
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Data was analyzed using FlowJo version 9.9.4 software (TreeStar).
Assay background and determining non-specific effects of
peptides is shown in Figure S5A. Background unstimulated
median CD4T cell IFNγ and IL2 frequencies were 0.05 and
0.07%, respectively, range 0.03–0.08%. Six IGRA− subjects tested
showed a very weak response to a set of five peptides tested
(parent median 0.02%, range 0–0.175%; mutant median 0.0365%,
range 0–0.165%) (Figure S5B), that induced a strong response
in IGRA+ subjects tested in parallel confirming that these
peptides had negligible non-specific cytokine inducing effects in
this assay.
Data Availability
The sequences have been submitted at the NCBI Sequence Read
Archive under BioProject ID PRJNA235852.
RESULTS
Novel Patterns of T Cell Epitope Mutations
in Multiple Mtb Strains From India
The availability of an extensive collection of functionally
validated Mtb-specific T-cell epitopes, including those that map
to highly immunodominant (IMD) antigens (58), allowed us
to assess, for the first time, mutations within these epitopes
in a total of 79 Mtb strains in India. Based on inherent
genetic differences in circulating Mtb lineages in South-East
Asia and other regions of the world (16, 17), we identified the
number and nature of these mutations to differ from those
found in a recent study (15). We identified mutated TCEs by
conventional approaches as previously reported (13, 15) that used
a combination of a whole genome assembly-based methodology
and an SNP-based approach. Mutations were defined as amino
acid changes within the 79 Indian isolates identified relative to
reference Mtb strain H37Rv that comprised non-synonymous
mutations in the gene spanning a given epitope. We identified
a total of 138 mTCEs by screening 79 Mtb whole genomes
from India that were part of a larger study that characterized
some 5,310 global Mtb strains (16, 17). Excluding 69 mTCE
in the highly repetitive, difficult to sequence PE and PPE
gene families as previously reported (13, 15), reduced this
number to 69 mTCEs from 43 antigens. Sixty-four of these
Sixty-nine mTCEs (93%) were also identified using an SNP-
based approach (16) (Figure S1; Supplementary File 2), and
verified to be encoded by the correct orthologous genes (see
methods). The nature of mutations in these 64 high confidence
mutated TCEs encoded by 40 antigens (Figure 3A) in the 79
strains circulating in India was comprehensively analyzed as
described below.
The overall level of mutations at the antigen and
corresponding epitope level was determined (Figures 1A B,
respectively, Figure 3A). In addition, the proportion of
mutations in a subset of 33 recently identified immunodominant
antigens (58) was also assessed (Figure 1C). At the antigen
level, 15% (5/33) overall mutation frequency was noted
(Figure 1A), whereas the proportion within immunodominant
TCEs was low (2%, 6 out of 248 TCE’s encoded by the 33
immunodominant antigens). Although only a low proportion
of epitopes encoded by these immunodominant antigens was
mutated, the overall proportion of mTCE relative to all 905
parent epitopes analyzed was higher (7%, 64/905), reflecting
focused mutations within few immunodominant antigens
(Figure 1B). Thus, only five of the 33 immunodominant
antigens carried mutations encoding 6 mTCEs (Figure 1D).
Among five, three of these immunodominant antigens belonged
to the “cell wall and cell processes” functional category
(Rv0289/espG3, Rv0987, Rv3019c/esxR), and two belonged
to the “intermediary metabolism and respiration” category
(Rv0291/mycP3, Rv0294/tam).
A number of features of the mutated TCE identified are
novel: (1) Although 97% of mutations represented single amino
acid changes, 3% of mTCEs contained two amino acid changes
(Figure 1C) (2) Two mTCEs had at least two different mutant
forms (n = 4) (Figure 1B); these mTCEs are of specific interest
as multiple variants of a single epitope can arise due to
immune selection pressure with functional consequences (see
Figure 4). (3) The 64 mTCEs identified spanned all known Mtb
functions (45), of which 44% belonged to the “cell wall and
cell processes” functional category (Figure S2), in keeping with
the proportion of parent epitopes in each category. (4) The
availability of detailed clinical records enabled us to interrogate
if mTCE patterns were skewed by the clinical stage of the
infected host. Figures S3A–E reveals remarkable consistency
in the number of mTCE that arise within the five clinical
groups analyzed, with a median of 7 mTCEs per strain tested,
each of which was isolated from a single infected donor
[range 5–13]. Importantly, none of the 79 strains analyzed
lacked an mTCE, of which 19% were common to all clinical
groups (Venn Diagram, Figure S3F). (5) In addition, we were
able to interrogate the stability of intra-donor mutations and
demonstrate in an analysis of six subjects, that multiple strains
[range 2–5 strains] isolated from a single donor over several time
points consistently resulted in identifying exactly the same TCE
mutations (Supplementary File 6).
Next, a genome-wide SNP-based phylogenetic map of the
79 Mtb strains (y-axis) was constructed and correlated with
the 64 mTCEs identified in the 79 strains from India (see x-
axis list for mTCE ID) (Figure 2). These 79 Mtb strains from
India grouped into three lineages: East African Indian (EAI)
(N = 54), Central Asian Strain (CAS) (N = 15), and Beijing
(N = 10), with each black square on the map representing an
mTCE. Fifty percent (32/64) of the mTCEs occur in a single
strain (represented by a single black square per column). Of
the 64 mTCEs, 91% (N = 58) were lineage specific. Only
five of the 64 mTCEs identified (Epitope ids: 67588, 153959,
155973, 178755, 179016), were common to all three lineages,
present in 90–100% strains and therefore highly prevalent
(Table S1). Importantly, only 3 of the 64 mTCE identified were
previously reported in the large Coscolla et al. (15) study that
analyzed 216Mtb strains (15). Taken together, these data confirm
the specificity of TCE mutations in Mtb strains circulating
in India to differ markedly from those recently reported in
the rest of the world (16). Given that 91% of mTCE we
report are lineage specific (Figure 2), inherent phylogenetic
differences between the strains we analyzed and those previously
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FIGURE 1 | Patterns of mutated antigens (mAg) and mutated epitopes (mTCEs) across 79 Mtb strains. The set of T-cell antigens and epitopes, as well as a subset of
immunodominant (IMD) antigens and epitopes, were analyzed based on their nature and locus in the Mtb reference strain H37Rv genome. (A) The total number of
reference/parent T cell antigens (blue), the number of mAg (red), and the number of parent immunodominant antigens and mutants analyzed is shown. (B) The total
number of reference/parent T-cell epitopes (blue), the number of mTCE (red), and the number of immunodominant parent T-cell epitopes and mutants are shown. The
green bar identifies mTCE with two or more mutant forms. (C) The number of mTCE with one vs. two amino acid changes is shown (blue bar represents total mTCE;
red bar immunodominant mTCE). (D) Representation of mTCEs in immunodominant antigens: A total of 33 of 82 antigens identified by Lindestam et al. (58) was
confirmed to be represented in the list of 298 reference antigens analyzed. Bars identify frequency of five mutated immunodominant antigens in 79 Mtb strains.
studied (15), may be one major factor contributing to
this difference.
Evidence for T-Cell epitope Mutations in
Rapidly Diversifying Proteins of Mtb
Genomes From India
Beyond phylogeny, host driven immune selection pressure
can influence T-cell epitope changes. Typically, such changes
would be expected to occur in rapidly evolving regions of a
pathogen genome. To probe this possibility, we determined
the nucleotide diversity scores of all 4,038 proteins encoded
by the 79 Mtb genomes from India (59), that have already
been verified and published (16, 17) as part of a larger
study that characterized 5,310 global Mtb strains. In addition,
we rigorously excluded genes from repetitive regions in our
screen of mutations; so as to consider only those mutations
with highest confidence, as reported previously (13, 15). The
median nucleotide diversity score of the top 10% of remaining
genes in the 79 Mtb whole genomes from India (N = 364;
excluding repetitive genes) was 0.00095 (range 0.00068–0.01006)
(Figure 3B; Supplementary File 3). Interestingly, this was higher
(p < 0.0001, Mann-Whitney test) than the nucleotide diversity
score (median 0.00081; range 0.00060–0.00459) of the top 10%
of diverging genes in 216 Mtb strains previously studied (15).
The nucleotide diversity score of the 40 antigens encoding all 64
mTCEs identified was marginally higher than the total 298 parent
T-cell antigens considered (Figure 3B). We determined if the
top 10% of diversifying genes in the 79 strains studied encoded
any of the 64 mTCEs identified. Within this set, 6 antigens were
identified with an exceptionally high median nucleotide diversity
score (Figure 3C), encoding 7 mTCEs. These seven mTCEs were
therefore identified to be the most rapidly evolving of the 64
mTCEs identified (Table 1; Supplementary File 3).
Evidence for Functional Impact of
Identified mTCEs
Immune selection driven T-cell epitope mutations invariably
impact the functional response. We successfully synthesized
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FIGURE 2 | Schematic representation of the phylogenetic relationship of mTCEs of all 79 Mtb strains. Maximum Likelihood tree shows the phylogenetic relationship of
the 79 strains studied, based on SNP data. The phylogeny shows two major clades, one consisting of 54 EAI lineage strains (pink), and another one consisting of two
clusters, including 10 Beijing/BEI (blue) and 15 CAS (purple) lineage strains, following the naming convention in Comas et al. (13). Each of the columns represents one
of the 64 mutated T-cell epitopes. The presence of a mutation in a particular strain is represented by a black square.
and screened 36 out of the 64 mutated TCE identified (56%)
in a functional assay. The immunogenicity of the novel T
cell mutant peptides and their respective naturally occurring
parental sequences, which spanned all functional categories of
Mtb proteins, were evaluated by quantifying IFNγ in cell culture
supernatants after antigenic stimulation of whole blood samples
from IGRA+ or LTBI and active PTB patients. We first screened
all 36 peptides for their capacity to induce IFNγ release measured
by ELISA, with a cut-off for a positive IFNγ response set at 5
pg/ml based on assay detection limits (Figure S4A). 32/36 (89%)
parent-mutant peptide pairs tested induced a IFNγ response in
IGRA+ subjects with latent TB compared to only 12 of these pairs
(33%) inducing a response in subjects with PTB (Figure S4A).
17/36 (47%) peptide pairs induced a response in >=25% of
the IGRA+ donors tested. 11/17 (65%) of these mTCE had a
differential response compared to the parent peptide (Figure S6).
In contrast to the response induced in IGRA+ subjects,
only 7 of 36 peptide pairs (19%) had a response frequency of
25% or higher in PTB subjects. This lack of response in PTB
subjects likely reflects specific impairment of epitope-specific
responses as the same PTB subjects responded efficiently to
an immunodominant recombinant TB antigen, ESAT6/CFP10,
similar to a PHA positive control (Figure S4B). This is consistent
with data showing subjects with PTB to have compromised
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FIGURE 3 | Genetic diversity of 79 Mtb strains from India. (A) The scale of the chromosome (in nucleotides, according to the reference Mtb strain H37Rv) is labeled
on the innermost ring. From the outer to the inner concentric circle of the chromosome: Circles 1–2 and 3–4, genes with forward and reverse directions are indicated
as right and left arrows, respectively. Circles 1 (green) and 4 (red) exemplify the locus of 40 mutated T-cell antigens, which encode mutated T-cell epitopes identified in
this study. Circles 2–3 (gray) depict all genes from H37Rv. Circles 5 (green) and 6 (red) show the locus of 64 mutated T-cell, epitopes in the forward and reverse
strands, lining their respective genes in circles 1 and 4, respectively. Circles 7 and 8 represents the GC skew of all the genes of H37Rv. (B) Bar graph showing
nucleotide diversity scores of genes from different categories (****p-value <0.0001). (C) Bar graph showing nucleotide diversity scores of six genes encoding mTCEs
that fall within the top 10% of nucleotide diversity scores across all 3,643 genes (excluding repetitive genes) encoded by the 79 Mtb strains from India, and therefore
designated as rapidly evolving.
blood T cell responses to several Mtb antigens, including latency
antigens whilst preserving responses to few immunodominant
secreted Mtb antigens, especially at the site of infection in the
lung (8, 9). Low frequencies of circulating blood Mtb-specific T
cells could therefore be one reason for the lack of response to a
broad range of parent and mutant T cell peptides in PTB subjects
reported in our study.
We next screened 9 of the peptide pairs that induced a
marked IFNγ response in IGRA+ subjects (marked with a
pink arrow—Figure S4A) by the more sensitive ICS to confirm
that the peptides indeed induced CD4T cell responses using
PBMCs from IGRA+ subjects. At first, frequencies of IFNγ
and/or IL2 expressing CD4T cells were measured in response
to stimulation with these 9 peptide pairs that represented
diverse functional categories. Relative to corresponding
parent peptides, 2 mTCE induced a significantly higher
response; responses to 5 mTCE was significantly impaired
and responses to 2 mTCE did not significantly differ from
parent (Figure 4). These same set of peptides either totally
failed to induce responses or induced very weak responses
in IGRA− subjects, highlighting specific recognition of these
epitopes by infected subjects (see representative FACS plot
and a graph depicting summarized response to set of five
peptides, Figure S5).
Out of the 9 peptides tested, 6 were rapidly evolving with
3 each from the immunodominant and non-immunodominant
categories. Importantly, EsxR (Rv3019c), an immunodominant
antigen belonging to the functional category cell wall and
cell processes and is rapidly evolving, encoded two mTCE
with one mutant form each; out of the two only one (M2-
5) but not M2-6 induced significantly higher responses than
their respective parent peptide, (P1-5 and P1-6) (Figure 4A).
In contrast, another mTCE of the intermediary metabolism
and respiration functional category and immunodominant
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TABLE 1 | List of known T-cell antigens carrying mutated epitopes present in the top 10% of rapidly evolving genes of 79 Mtb strains isolated in India.
Rv
Number
Gene name Protein
name
Functional category # mTCE Proportion of
strains carrying
mTCE
Lineage Nucleotide
diversity score
Rv0294 Tam Trans-aconitate
methyltransferase
Intermediary
metabolism and
respiration
1 52 EAI 0.00182
Rv0988 Rv0988 Hypothetical protein Rv0988 Cell wall and cell
processes
1 6 EAI 0.00126
Rv1769 Rv1769 Hypothetical protein Rv1769 Conserved
hypotheticals
1 32 CAS, BEI 0.00078
Rv2628 Rv2628 Hypothetical protein Rv2628 Conserved
hypotheticals
1 68 EAI 0.00119
Rv3019c esxR ESAT-6 like protein EsxR Cell wall and cell
processes
2 33 EAI 0.00152
Rv3879c espK ESX-1 secretion-associated
protein EspK
Cell wall and cell
processes
1 11 BEI 0.00079
antigen Tam (Rv0294, M4-3), which is also rapidly evolving
elicited lower frequencies of IFNγ and/or IL2 compared to the
parent peptide (P3-3, Figure 4A). Next we tested three rapidly
evolving non-immunodominant peptides, of which two mTCEs
belonging to functional category cell wall and cell processes,
had opposing effects on the CD4T cell response, whereby
Rv0988 (2-D03M) and Rv3879c (espK, 2-A11M) displayed
significantly enhanced and decreased frequencies, respectively.
On the other hand, mTCE encoded by Rv1769 (2-A06M),
a conserved hypothetical protein did not exhibit any loss or
gain in the overall CD4T cell response as reflected by the
insignificant change in frequencies of IFNγ and/or IL2 CD4T
cells compared to the parent peptide (Figure 4B). Additionally,
three more non-immunodominant peptides that are not rapidly
evolving were also tested by the ICS assay. Rv1733 (2-A02M)
common to all three lineages and Rv2029c (pfkB, 2-C04M),
two well-known DosR regulon encoded latency antigens (60)
(Figure 4C) significantly reduced IFNγ and/or IL2 frequencies
relative to parent. Previous studies show latency antigens
(Rv1733, Rv2029, and Rv2628—we report on novel mTCE in
all three of these antigens) to be better recognized by subjects
with latent TB compared to those with disease (8, 61–64).
Similarly, the other mTCE of GroEL2 (Rv0440, 2-C01M) protein
belonging to the functional category virulence detoxification
and adaptation, also significantly impaired responses compared
to the parent CD4T cell responses by 9 of these peptides
tested above concurred with the whole blood IFNγ release assay
(data shown only for 2-D03M and M4-3 in Figure S6). In
order to further investigate if any of these peptides induced
an altered cytokine response, we tested all 6 rapidly evolving
peptides for regulation of a further three cytokines: TNFα, IL17A,
and MIP1β. We demonstrate that changes in frequencies of
the three additional cytokine-positive CD4T cells (Figure S7)
followed exactly the same pattern as IFNγ and/or IL2 shown
in Figures 4A,B for these 6 peptides. Taken together, these
data confirm that 7/9 mTCE tested in the ICS assay have
a significant functional consequence on Mtb-specific CD4T
cell responses.
Changes in the Predicted Binding Affinity
of mTCE to Common Indian HLA-Class II
Alleles Is Associated With mTCE-Induced
Changes in T-Cell Responses
HLA is a major driving force in shaping immune escape, and
therefore T-cell mutations. We therefore predicted that changes
in HLA Class-II binding affinity of mTCEs may correlate with
functional changes in the immune assays described in Figure 4.
Therefore, an in silico analysis of the binding affinity of the
identified mTCEs to 55 common Indian HLA-DR and 6 DP and
6 DQ alleles, was conducted, using the well-known IEDB analysis
resource consensus tool (47–50) which is programmed to analyse
peptides/TCEs that are 15-mer in length. A total of 20/64 mTCE
were 15-mers. These were analyzed using a binding score of 10
as a cut-off (IC ≤ 10 nM), to identify those with high binding
affinities for HLA Class-II alleles and therefore more likely to
have a functional consequence. Consistent with publications (65–
67), we show that all 20, 15-mer Mtb mTCE/parent peptides
tested were predicted to bind to multiple HLA-DR alleles. In
this in silico analysis, 10 HLA-DR alleles bound >55% peptides
with high affinity (see Figure 5A: arrow identifies alleles that are
predicted to bind rapidly evolving mTCE). In contrast only a
few peptides bound DP (N = 5/20) and DQ (N = 8/20) alleles
with high affinity (Figures 5B,C).MostmTCEs showed improved
HLA–DR binding relative to parent (red bar Figures 5A–C).
We next determined if changes in HLA-DR binding of mTCE
(relative to parent) were associated with functional changes.
Out of 36 peptides synthesized and tested for function, only
13 were 15-mer peptides (Supplementary File 2; Sheet 2). In
Figure 5D, we demonstrate the changes in HLA-DR binding of
these 13mutant peptides relative to its parent. The data highlights
changes in the binding affinity pattern of each mTCE to be
strikingly similar to the functional data shown in Figure S6 for
these same 13 peptides. Thus, mTCE: 2-D02M, 2-D03M, 2-
D07M, M2-10, 2-A04M, and 2-A12M induced higher T-cell
responses (Figure S6A) concomitant with increased Class II
binding affinity reflected by a significantly reduced binding
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FIGURE 4 | CD4T cell responses to parent and mutant peptides. PBMCs from IGRA+ subjects were stimulated overnight with parent and mutant peptides that are
either rapidly evolving or not-rapidly evolving and belonging to immunodominant and non-immunodominant category. Frequencies of IFNγ+ and/or IL2+ CD4T cells
were determined by ICS assay (see methods). Line graphs shows IFNγ and/or IL2 CD4T cell frequency following stimulation with a set of nine parent and mutant
peptides as individual plots in IGRA+ subjects after subtraction of background unstimulated control. Each line is a donor. Statistical analysis was performed using
nonparametric Wilcoxon matched-pairs signed rank test. *P < 0.05 was considered significant. mTCE were grouped as follows: (A) Rapidly evolving and
immunodominant Rv3019c (EsxR) and Rv0294 (tam). (B) Rapidly evolving and non-immunodominant Rv0988, Rv3879c (espK) and Rv1769. (C) Not rapidly evolving
and non-immunodominant Rv1733, Rv2029c, and Rv0440.
score compared to parent (Figure 5D). In contrast, mTCEs M4-
3, 2-A03M, 2-A10M, 2-C05M, and 2-C09M displayed HLA
binding scores that were significantly enhanced compared to
parent, consistent with reduced T cell responses (Figure S6B),
associated with decreased Class II binding affinity (Figure 5D).
Moreover, mTCE 2-A09 and 2-C11M, which did not induce
significantly different T-cell responses to parent (Figure S6C)
bound fewer Class-II alleles with minor differences in binding
affinity between parent and mutant (Figure 5D). Taken together
these data highlight that mutations in the T-cell epitopes
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FIGURE 5 | Binding of T-cell epitopes to Indian HLA-DR/DP/DQ alleles. (A) Proportion of a 20 mutant TCEs (15 mer; red) and their corresponding parent/reference
TCEs (blue) restricted by 55 HLA-DR alleles identified in the Indian population. Only epitopes with binding affinity score IC≤10 nM were considered. (B) Binding to DP
alleles and, (C) Binding to DQ alleles. (D) Binding affinity of 13 selected 15 mer parent and mutant peptides to DR alleles, which predict gain or loss or no change in
function–see Figure S6 for corresponding IFNγ release data.
identified can potentially impact binding to HLA-DRB1 alleles
in particular.
Evidence for HLA Class II Selection of
Region-Specific mTCE in Mtb Strains From
India
Screening for amino acid changes in the mTCEs identified
against a SNP database of 5,310 Mtb whole genome sequences
enabled the contextualization of T-cell epitope mutations in
a large collection of global Mtb strains. Among 5,310 Mtb
strains, 220 were from India (16), including the 79 we initially
used to identify mTCE by the annotation-based and SNP-based
methods (see Figure S1, Supplementary File 2, and Figure 6A
for overview of analysis). The 64 mTCE matched 66 SNPs
and identified four distinct clusters of Mtb strains: (i) mTCE
exclusive to strains from India (N = 36/66 = 54.5%); (ii) mTCE
enriched (and therefore more likely to be identified) in strains
from India (N = 18/66 = 27.3%); (iii) mTCE in near equal
proportion in strains from India and outside India (N = 8/66
= 12.1%) and (iv) mTCE enriched in strains outside India i.e.,
rare in India (N = 4/66 = 6.1%). The majority of mTCEs
identified (82%) fell in groups (i) and (ii) above; they were either
exclusive to Mtb strains circulating in India or occurred at a
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FIGURE 6 | Global distribution of 64 mTCEs and relationship to HLA-DR binding. (A) Flow chart shows the number of mTCEs identified in 79 Mtb strains from India,
and their frequency in the context of non-synonymous SNPs (nSNPs) identified in 5,310 globally distributed Mtb strains (18, 60). After excluding mTCEs from repetitive
regions (n = 69/138), the remaining 69/138 mTCEs were mapped to nSNPs of 5,310 global Mtb strains, in which 64/69 mTCEs matched to corresponding 66 SNPs
(some mTCEs have more than one mutation with each mutation corresponding to one SNP). These 66 SNPs in 64 mTCEs were classified into four groups based on
their global geographic distribution in 5,310 Mtb strains as follows: mTCE exclusive to India; mTCE enriched in India; mTCE in equal proportion inside and outside
India and mTCE enriched outside India. Of the 4 groups of mTCE identified, those that were significantly exclusive to (N = 36) enriched (N = 15) or enriched outside
India (N = 4) as determined by Fischer’s exact test adjusted for multiple comparison with a p-value cut-off of <0.001 is shown. Only for one group: mTCE in equal
proportion in both India and outside India (N = 8) all the mTCEs identified is shown irrespective of significance. (B) Each bar is an mTCE (IEDB Epitope ID of
corresponding reference epitope) (X-axis list) that corresponds to the proportion of prevalence of mutation (Y Axis list) in India (black square) vs. outside India (gray
square). Red arrow above the bar represents rapidly evolving epitopes. (C) Paired line graph show the frequency (percentage) of all 15-mer mTCE from each of the 4
groups listed in Figure 6B binding with high affinity (<10 nM) either to 16 HLA-DR alleles that are common in India (but also prevalent outside India) vs. a total of 34
HLA-DR alleles that are either not common in India or not reported in India. P-value determined by Wilcoxon matched-pairs signed rank t-test.
median 12.4-fold higher frequency in strains isolated from India
compared to the rest of the world (range 2.2- to 156.2-fold higher)
(Supplementary File 2; Sheet 3). Analysis of lineage distribution
shows that mTCE accumulating in India largely include EAI
and CAS strains and mTCE accumulating equally in India and
outside India include the Beijing strains. A proportionality test
adjusted for multiple comparisons identified mTCE that were
significantly enriched in India vs. outside India and these are
listed in “x” axis of Figure 6B. These data confirm the majority
of T-cell epitope mutations reported in this study (82%) to occur
significantly more frequently in strains circulating in India; only
6.1% of mTCEs identified were more prevalent in strains outside
India (Figures 6A,B).
We next determined if this region-specific occurrence of
mTCE was determined possibly by preferential binding to HLA
Class-II alleles common in India vs. the rest of the world, given
the recognized critical importance of HLA in driving immune
selection. We hypothesized that the ten mTCEs (15-mer) that
were exclusive to India (Figure 6B; Supplementary File 4) would
bind preferentially to HLA Class-II alleles that were highly
prevalent in India but rare in the rest of the world. To test this
possibility, all 15-mer mTCEs of the 64 mTCE identified were
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probed for predicted binding to two major groups of HLA-DR
alleles: Group A included 16 DR alleles that are highly prevalent
in India, but also found outside India. Group B included 34
HLA-DR alleles that were either rare in India (N = 11) or
absent in India (N = 23). To note: we did not identify any
HLA-DR alleles exclusive to India, which were absent from the
rest of the world. Figure 6C shows a Wilcoxon paired analysis
comparing the percentage of Group A vs. Group B HLA-DR
alleles, with predicted binding to each of the mTCE tested. In
keeping with our prediction, the 10 mTCEs exclusive to India
showed significantly higher predicted binding to HLA-DR alleles
prevalent in India compared to DR alleles rare in India (p =
0.0039) whereas mTCEs that were enriched but not exclusive to
India showed equally efficient predicted binding to both groups
of DR alleles (p = 0.4375). All 15-mer mTCEs tested showed
high affinity predicted binding to multiple DR alleles (>60%)
prevalent in India (Figure 6C: refer to median percentage of
each group of mTCEs binding to Group A DR alleles), with the
exception of mTCEs equal in India and outside India and mTCEs
enriched outside India, which showed predicted binding to only
few (<35% median) DR alleles. Interestingly, HLA-DRB1∗03,
HLA-DRB1∗04 & HLA-DRB1∗08 have been associated with TB
protection/disease (68, 69); Group-A includes HLA-DRB1∗03:01,
∗04:02, ∗04:08, and ∗04:10 all of which bind ≧60% (>12/20)
peptides tested with high predicted binding affinity. Together,
these data provide strong evidence thatMHCClass II DR binding
patterns likely reflect whether an mTCE is (i) exclusive to India,
(ii) enriched in India but can be found infrequently globally, (iii)
in equal proportion in India vs. the rest of the world or (iv)
enriched outside India.
DISCUSSION
This study provides compelling evidence that (a) functional
mutations in Mtb-specific CD4T cell epitopes are not
uncommon in Mtb strains isolated from infected subjects living
in India—each of the 79 Mtb strains isolated from 79 infected
subjects carried on average 7 mTCE (Figure 1, Figure S3); (b) the
vast majority of SNPs in mTCEs that we report are region specific
(Figure 6A) and either found exclusively in strains from India
or to occur significantly more frequently in strains from India
(Figure 6B); (c) 15.7% of mutated epitopes reported bear the
hallmarks of emergence due to immune selection pressure with
higher nucleotide diversity scores than the corresponding parent
T cell epitope currently curated in the Immune Epitope Database
(Figures 3, 4); and (d) in silico analysis shows altered binding
of T cell epitopes to MHC Class-II HLA-DR alleles to be a
potentially important mechanism contributing to the emergence
of these region-specific T-cell epitope mutations in Mtb. Whilst
the overall number of mutations in known T cell epitopes
remains low, in keeping with previous reports highlighting TCE
mutations to be rare in Mtb (13, 15), it is clear that all Mtb strains
from India tested carry multiple mTCE (Figure S3), of which
only seven have been previously been reported (13, 15). Sixty-
two percent of mTCE tested have a functional consequence on
CD4 T-cells IFNγ secretion, which is associated with predicted
changes in MHC Class-II binding (Figure 5). Most importantly,
the 64 mutations we report have been verified in an extensive
database of SNP’s generated on 5,310 global Mtb strains (46).
Taken together, our study provides a comprehensive analysis of
TCE mutations in Mtb and highlights an underappreciated level
of region-specific TCE diversity accumulating in Mtb strains.
The remarkable diversity in T-cell epitope mutations in Mtb
strains circulating worldwide vs. India highlights the underlying
significance of regional differences in shaping their evolution
in genetically (HLA) and environmentally (e.g., NTM) different
regions. Despite analysis of a significant number of lineage-1-
strains in the Coscolla et al. (15) study, very few (n = 3) of
the mutations they report were found in our strains and vice
versa. Although multiple strains isolated from a single donor
over time reveal stability of mutations (Supplementary File 6),
an analysis of the 79 strains isolated from India shows only
19% of the mutated epitopes to be common (Venn diagram,
Figure S3), highlighting significant variation in T cell epitope
mutations even within donors who map to a single geographical
region. The fact that most mutated TCE reported in this study
are lineage-specific highlights that changes in proteins that
diverge between lineages can include proteins that encode TCEs.
Our study also highlights that some lineage-specific TCEs may
evolve due to immune selection pressure. Thus, 7 of the 64
total mTCEs that map to highly rapidly diversifying regions
of the bacterial genome, which impact T-cell function and are
present in multiple strains, are majorly found within the EAI
lineage (Table 1). In addition, we identified five mTCEs that
were common across three lineages and prevalent in ≧90% of
strains studied; only one of these has been previously reported
(13, 15). The top 10% of genes, in terms of nucleotide diversity,
in Mtb strains from India encoded none of these five very
common mutated epitopes. Therefore, the process that governs
the selection of these highly common TCE mutations would be
predicted to differ from those that are rapidly evolving and may
be linked to more fundamental bacterial survival. Together, these
observations indicate that diverse mechanisms may account for
the unique patterns of T-cell epitope mutations accumulating in
Mtb strains.
Previous studies (13, 15) have implied that immune escape
from T-cell responses is unlikely to be a major factor contributing
to Mtb diversity and persistence, on the basis that only a
small percentage of known T cell epitopes that can induce an
immune response are mutated, despite clear evidence that the
bacterial genome itself is evolving. Whilst our study concurs
with this notion (13, 15), this observation needs to be placed in
context of data that suggest that current studies underestimate
the number of TCEs in Mtb. For example, Coscolla et al.
(15) recently highlighted the presence of several new TCE,
not curated previously in the IEDB, encoded by Mtb proteins
that are rapidly diversifying, which carry functional mutations.
This, along with our data emphasizes the importance of
probing highly diverging genes of Mtb for TCE mutations.
Indeed, the analysis of complete genome sequences from clinical
isolates has identified the Mtb genome to carry SNPs, large
sequence polymorphisms (LSPs), and regions of difference
(RDs) originating from small deletions, deletions in homologous
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repetitive elements, point mutations, genome rearrangements
and frame-shift mutations (70). The significance of this inherent
genetic variation is not fully understood, but has been suggested
to denote selective pressure and therefore be important in
bacterial pathogenesis and immunity (70, 71). In our study, given
that screening the large global Mtb genome SNP database of
5,310 strains confirmed the mutated epitopes identified to be
largely region-specific, we did not apply selection analysis as
calculating the non-synonymous vs. synonymous substitution
changes (dn/ds) are not deemed appropriate for strain level
analysis within a species, though suitable for inter-species level
comparisons (72).
These observations of Mtb diversity in the context of our data
call for further functional studies onMtb-specific TCE changes to
better understand their impact on immune escape and bacterial
persistence. In addition, studies are needed to verify epitopes
predicted within highly divergent regions. One limitation of our
analysis is known difficulties in interpreting sequencing data
from repetitive regions of the genome, particularly when data
are generated from a single sequencing library of short genomic
fragments as in this study. For instance, ESAT-6 encoding
regions are known to be difficult to sequence, assemble and align
using short read technologies causing errors that could inflate
nucleotide diversity estimates. However, previous works using
similar data have reported on TCEmutations in these same genes
(13, 15) and we also elected to follow up only on those variants
appearing in both assembly and variant detection analyses thus
minimizing this issue. In this case, only one epitope identified in
a repetitive gene ESAT-6 was retained, which showed 2 variants,
especially as this particular mutation was previously reported to
have a functional consequence.
The discovery that immune selection pressure can potentially
drive TCE mutations in Mtb and our data that emerging TCEs
differ markedly between Mtb strains circulating worldwide vs. in
India, has implications for vaccine design. Firstly, our data and
those of Coscolla et al. (15), pave the way for these new epitopes
with functional impact in proteins that are rapidly diversifying to
be validated for their ability to detect T-cells that correlate with
protection. If validated, this will greatly improve vaccine design
by enabling focused efforts on vaccines designed to induce T-
cells with such specificities. Further, the accumulating evidence
that the T-cell epitope landscape is likely globally diverse and
evolving, emphasizes the need to factor this information in future
vaccine design. Taken together, our data therefore provides novel
insight to a key, understudied aspect of TB immunity: namely, the
nature and pattern of CD4T-cell epitopemutations accumulating
in Mtb genomes.
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Figure S1 | Pipeline for TCEs screening. Flow chart shows the number of T-cell
epitopes retrieved from IEDB, number of TCEs identical to reference Mtb strain
H37Rv and their corresponding antigens, and number of TCEs finally considered
for further analyses.
Figure S2 | Pie chart representing functional categories of mTCEs and
reference/parent TCE. (A) 64 mTCEs; (B) Parent 905 TCEs.
Figure S3 | mTCEs by clinical classification. All 79 strains were classified into five
clinical groups. Strains in each of 5 groups are further classified into 3 subsets:
good, bad and default, based on their clinical outcomes. Stack bars represented a
total number of mTCEs in each of 79 strains studied. (A) 26 drug sensitive (DS)
HIV-negative strains, (B) 22 DS HIV-positive strains, (C) 12 poly-resistant (PR)
HIV-negative strains, (D) 15 multi drug-resistant (MDR) HIV-negative strains,
(E) 4 MDR HIV-positive strains, and (F) Venn diagram based on 53 mTCEs
sequences from 5 different clinical categories, showing mTCEs that are common
and unique to each category. Only epitopes that are annotated in all 79 Mtb
strains were considered for this analysis, after excluding epitopes encoded by
partially annotated antigens in some strains. Clinical outcomes—Good, patient
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successfully treated; Bad, patient not cured of TB; Default, patient relapsed
during treatment.
Figure S4 | Novel epitopes induce a stronger IFNγ response in IGRA+ individuals,
but response to immunodominant antigens are similar in both clinical groups. (A)
Diluted heparinized whole blood from 12 IGRA+ individuals and 6 PTB patients
were stimulated with a total of 36 parent and corresponding mutant peptides at
1µg/ml final concentration for 7 days. Summarized data shows the proportion of
responders in the 7-day whole blood IFNγ release assay to a total of 36 parent
(blue) and corresponding mutant (red) peptides in IGRA+ and PTB subjects, with
a cut-off for a positive IFNγ response set at 5 pg/ml. Peptides that induced
responses in >=25% of donors tested are indicated with a horizontal black line.
Nine peptides marked by pink arrows were also simultaneously tested in ICS
assay as shown in Figure 4. Thirteen 15 mer peptides representing parent and
mutant sequences of epitopes marked by green asterisks were selected for HLA
binding assay as shown in Figure 5 and whose IFNγ response is illustrated in
Figure S6. (B) Diluted heparinized whole blood from 10 healthy IGRA−
individuals, 10 latent TB-infected (IGRA+) and 10 pulmonary TB (PTB) were either
left unstimulated or stimulated with Mtb antigens ESAT6/CFP10 and PPD at
10µg/ml and positive control PHA (3µg/ml) for 7 days. Scatter plot shows IFNγ
levels in the supernatants measured by ELISA after background unstimulated
control value subtraction. Each dot represents a donor. Data was analyzed using
Non-parametric One-Way ANOVA Kruskal-Wallis test and Dunn’s multiple
comparisons test. Significant differences are indicated: ∗∗p < 0.01.
Figure S5 | mTCEs induce a highly specific CD4T cell response in IGRA+
subjects. (A) PBMCs from IGRA+ and IGRA− subjects were stimulated overnight
with rapidly evolving immunodominant parent (P3-3, upper panel) and mutant
peptide (M4-3, lower panel). Representative flow cytometry plots depicting IFNγ+
and IL2+ CD4T cells upon stimulation of PBMCs in IGRA+ (left) and IGRA− (right)
is shown. (B) IFNγ and/or IL2 CD4T cell frequency following stimulation with a set
of five parent and mutant peptides in six IGRA− subjects after subtraction of
background-unstimulated control. The mean/SD response frequency in the six
IGRA− donors to each of the five parent and mutant peptides tested is shown as
five lines (one line per peptide pair). Median responses in IGRA− subjects to the
peptides tested, after background subtraction, was: parent peptide median 0.02,
range 0–0.175; mutant median 0.0365, range 0–0.165. These data confirm these
peptides to have negligible non-specific stimulatory effects in this assay.
Figure S6 | Whole blood IFNγ levels in response to 13 15 mer synthetic peptides
representing parent and mutant sequences of epitopes selected for HLA binding
assay. IFNγ ELISA was performed on supernatants collected after 7-day
stimulation of diluted heparinized blood from IGRA+ and PTB subjects with
peptides. Each graph shows the concentration of IFNγ (pg/ml), which either
induces gain (A) or loss (B) or no change in function (C). Each line represents
IFNγ levels induced by a given donor in response to the parent vs. the mutant
peptide assayed simultaneously after subtraction of background-unstimulated
control. Statistical analysis was performed by Paired Wilcoxon signed-rank test.
Figure S7 | CD4T cell responses to parent and mutant peptides. PBMCs from
IGRA+ subjects were stimulated overnight with parent and mutant peptides that
are rapidly evolving and belonging to immunodominant and non-immunodominant
category. Frequencies of IFNγ+, IL2+, TNFα+, IL17A+, and MIP1β+ CD4T cells
were determined by ICS assay (see methods). Line graphs shows frequencies of
cytokine-positive CD4T cells following stimulation with a set of six parent and
mutant peptides as individual plots in IGRA+ subjects after subtraction of
background unstimulated control. Each line is a donor. Statistical analysis was
performed using nonparametric Wilcoxon matched-pairs signed rank test. ∗P <
0.05 was considered significant. mTCE were grouped as follows: (A) Rapidly
evolving and immunodominant Rv3019c (EsxR) and Rv0294 (tam) (B) Rapidly
evolving and non-immunodominant Rv0988, Rv3879c (espK) and Rv1769.
Supplementary File 1 | Frequency and length of T-cell epitopes analyzed. (A)
905 parent/reference TCEs, (B) 64 mTCEs.
Supplementary File 2 | Comprehensive data on 64 mTCEs identified and their
frequency in 5,310 globally distributed Mtb strains (18, 60). Sheet 1 contains the
total number of mTCEs (n = 138) that we initially identified in both non-repetitive
and repetitive regions of the 79 Mtb strains we studied, along with complete
relevant data. Sheet 2 contains the identical information of Sheet 1, but
excluding mTCEs (n = 69) from repetitive regions. Sheet 3 shows the matching
non-synonymous SNPs (nSNPs) from 5,310 globally distributed Mtb strains with
the mutations of mTCEs identified from non-repetitive regions of the 79 Mtb strains
we studied. In total, 64 mTCEs have a match in 5,310 global strains, but as some
of the mTCEs have more than one mutation, the total number of SNPs recorded is
66. Sheet 4 shows only those mTCEs from Sheet 3 that are rapidly evolving.
Sheet 5 shows all relevant information about the epitopes having multiple forms.
Supplementary File 3 | Nucleotide diversity of all the genes from 79 Mtb isolates
we studied from India.
Supplementary File 4 | HLA binding affinity prediction of all 15 mer
parent/reference TCE and their mutants (N = 20) to total of 50 MHC Class-II
alleles (http://allelefrequencies.net/). Allele frequency ≥0.01 is set-up as cut-off to
screen high frequency alleles. The 20 mTCEs are classified into four groups based
on their global geographic distribution in 5,310 Mtb strains as follows: mTCE
exclusive to India; mTCE enriched in India; mTCE in equal proportion inside and
outside India and mTCE enriched outside India. Total of 50 alleles are classified as
follows: Binding of each mTCE to 16 DR alleles (Group A) common in India (but
also prevalent outside India) was compared to 34 DR alleles (Group B) comprising
11 that are less prevalent in India but highly enriched outside India and 23 alleles
that are not reported to date in India, but prevalent in rest of the world
(geographical regions): Australia, Europe, North Africa, North America, North-East
Asia, Oceania, South and Central America, South-East Asia, Sub-Saharan Africa
and Western Asia. These 23 alleles are reported with high frequency in at-least
two of 10 geographical regions we considered. Predicted binding affinity of all four
groups of TCE/mTCEs are provided against all alleles we studied.
Supplementary File 5 | Clinical details of samples used for testing T-cell function
of mutant vs. parent peptides.
Supplementary File 6 | Details of intra-donor Mtb T-cell epitope mutations in six
subjects. A total of 17 Mtb strains (range 2–5 strains) were isolated from 6
subjects (Patient ID: P6, P38, P96, P97, P103, and P106). The total number of
Mtb strains isolated from each donor, along with number of mTCEs and mutated
antigens identified in strains isolated over multiple time points is summarized in
individual sheets of EXCEL this File for each of six donors tested.
Table S1 | Details of 5 mTCE identified in ≥90% of 79 Mtb strains from India.
Table S2 | Clinical details of individuals included in this study.
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